Latest News

National News

More medicines added to PBS: Hunt

The Morrison government is investing more than $86 million over the next four years to provide greater access to life saving medicines for Multiple Sclerosis suffers and for those with various forms of cancer.

From November 1, Mayzent(r) (siponimod) will be listed on the Pharmaceutical Benefits Scheme for the first time to treat those patients with secondary progressive multiple sclerosis.

Without the PBS subsidy, these patients would pay more than $25,000 per year for treatment, with some 800 patients benefiting from its listing each year.

The PBS subsidy now means patients will only need to pay $41 per prescription, or $6.60 with a concession card.

Among other PBS listings from November 1, Australians diagnosed with a rare type of lymphoma which affects the skin will receive subsidised access to a new medication and specialised treatment.

Uvadex(r) (methoxsalen) will be listed on the PBS for the first time for treatment of patients with erythrodermic cutaneous T-cell lymphoma who have not responded to other treatments.

Around 75 patients per year may benefit from this listing and without PBS subsidy, these Australians would pay more than $3400 per year.

"The Morrison government's commitment to ensuring that Australians can access affordable medicines, when they need them, remains rock solid," Health Minister Greg Hunt said in statement on Sunday.

© AAP 2020